Bioquell, a company which provides specialist bio-decontamination technologies to a range of markets, has admitted it suffered a 'slight shortfall' at the end of the year in orders expected for immediate shipment to Life Sciences customers based in continental Europe.
As a result, full year revenue is now expected to be £41.0m, compared to £41.3m in 2011.
The company also said it decided not to ship a number of orders before the year end from customers in the emerging markets because it was "unable to satisfy ourselves as to the robustness of the associated credit arrangements".
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The group added: "In addition, our defence invoicing in 2012 was held back at the very end of the year on one large defence contract due to slippage on matters unrelated to Bioquell's activities. Our business is highly operationally geared and such a reduction in revenues has a significant effect on our profitability.
"We estimate that the aggregate revenue effect relating to these matters will be approximately £0.9m."
Aside from this, the group has begun 2013 with a 12% increase in its opening order book of £17.2m (2011: £15.4m), with no significant change year-on-year in the defence order book. The Bio-decontamination division order book totalled £12.3m (72% of the total order book) and TRaC represented £4.9m (28%).
In 2012, the group took orders worth £44.6m, up slightly from £44.4m in 2011, with an 'encouraging' performance from TRaC, where orders rose 18%, and revenues climbed 11%. Both orders and revenues hit a monthly record in December.
Investec moved its target price from 137p to 130p and retained its hold rating on the stock.
The share price fell 7.81% to 147.50p by 12:30.
NR
-
Is a mortgage in retirement always a bad idea?A mystery shopper exercise shows high street lenders are “shunning” retirees looking to take out a mortgage. Are they right to do so?
-
Three funds to consider as UK small caps trade at 30% discountUK small caps have been unloved for some time, but a shifting economic environment could give them a boost
